Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease

Simple item page
dc.catalogadorpva
dc.contributor.authorDíaz Piga, Luis Antonio
dc.contributor.authorCollier, Summer
dc.contributor.authorYin, Jeffrey
dc.contributor.authorLoomba, Rohit
dc.date.accessioned2025-06-19T20:13:22Z
dc.date.available2025-06-19T20:13:22Z
dc.date.issued2025
dc.description.abstractBackground: Pharmacologic treatment of alcohol use disorder (AUD) in patients with advanced alcohol-associated liver dis-ease (ALD) remains underutilised due to concerns regarding hepatotoxicity. Injectable extended-release naltrexone (XR-NTX)may offer a safer alternative by avoiding first-pass hepatic metabolism, but data on its safety and effectiveness in patients withadvanced ALD are limited.Aim: To describe the clinical experience with XR-NTX in individuals with advanced ALD, evaluating its safety, tolerability andimpact on liver function and alcohol use.Methods: Retrospective case series of adults with ALD who received at least one dose of XR-NTX 380 mg IM at a tertiary carecentre between 2023 and March 2025. Clinical data and laboratory tests were extracted from electronic health records over aminimum follow-up of 12 weeks. Safety was assessed based on adverse events and liver biochemistry. Alcohol use was evaluatedusing phosphatidylethanol (PEth) levels.Results: Fourteen individuals with ALD were included (2 had F3 and 9 cirrhosis Child A–B). The median age was 51 [44–65]years, 64% were male, and median follow-up was 127 days. Four patients (29%) experienced mild adverse effects (injection sitepain, nausea and vomiting, fatigue and sexual side effects); none had hepatotoxicity or hepatic decompensation. No significantchanges in liver function tests or MELD/Child-Pugh scores were observed during the follow-up period. Eight participants (57%)had a decrease in alcohol consumption, with a non-significant decline in PEth levels.
dc.format.extent7 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1111/apt.70237
dc.identifier.eissn1365-2036
dc.identifier.issn0269-2813
dc.identifier.urihttps://doi.org/10.1111/apt.70237
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/104716
dc.information.autorucEscuela de Medicina; Díaz Piga, Luis Antonio; 0000-0002-8540-4930; 179253
dc.language.isoen
dc.nota.accesocontenido parcial
dc.publisherJohn Wiley & Sons Ltd.
dc.revistaAlimentary Pharmacology & Therapeutics
dc.rightsacceso restringido
dc.subjectAddiction treatment
dc.subjectAlcohol use disorder
dc.subjectAlcoholic cirrhosis
dc.subjectAlcohol-related liver disease
dc.subjectCirrhosis
dc.subjectHepatotoxicity
dc.subjectNaltrexone
dc.subjectPhosphatidylethanol
dc.subjectVivitrol
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleSafety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
dc.typeartículo
sipa.codpersvinculados179253
sipa.trazabilidadORCID;2025-06-16
Files
Collections
Artículos de revistas